This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.
Study Type
OBSERVATIONAL
Enrollment
95
Unnamed facility
Bucharest, Romania
Mean change in Disease Activity Score 28 (DAS28)
Time frame: 11 months
Proportion of patients with a change in Disease Activity Score 28 (DAS28)
Time frame: 5 months
European League Against Rheumatism (EULAR) response rates
Time frame: 20 weeks
Proportion of patients with disease remission
Time frame: 20 weeks
Proportion of patients with low disease activity
Time frame: 20 weeks
Incidence of adverse events
Time frame: 11 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.